HOME >> BIOLOGY >> NEWS
Breakthrough technology from Pall increases platelet availability and safety

East Hills, NY (October 5, 2005) -- Pall Corporation (NYSE: PLL) announced today FDA clearance to market the new Pall AcrodoseTM PL System. This is the first whole blood derived platelet system for pre-storage pooling and testing of leukoreduced whole blood derived platelets resulting in a transfusion-ready product for the hospital. This unique product increases the availability of lifesaving platelets, enhances patient safety and is more cost-effective for the hospital.

"Adequate platelet availability in some communities can sometimes be a challenge," says Allan Ross, President of Pall Medical. "The Acrodose PL System provides an opportunity for blood centers and hospitals to increase the availability of bacterially tested, leukoreduced, and pooled whole blood derived platelets in a cost-effective manner."

Platelets are derived from donors in either a one-to-two hour procedure called apheresis or from standard whole blood collections. Apheresed platelets are limited by donor availability. They are also time consuming and capital intensive to obtain. Regardless of which collection process is used, bacterial contamination of platelets is the leading infectious cause of illness and death from a blood transfusion. Single donor platelets are tested for bacterial contamination using a sensitive culture detection method such as Pall's eBDS, enhanced bacterial system. Whole blood derived platelet units on the other hand are tested using less sensitive methods due to cost, product loss, and logistical constraints of testing several individual units to obtain a standard therapeutic dose. This has resulted in a disparity of test sensitivities as well as underutilization of a valuable blood resource.

The new Acrodose PL System enables blood centers to pool individual whole blood derived platelets prior to storage and conduct a single bacterial contamination test with its integrated Pall eBDS technology. Studies using the Pall eBDS System with pooled p
'"/>

Contact: Marcia Katz
marcia_katz@pall.com
516-801-9128
Pall Corporation
6-Oct-2005


Page: 1 2

Related biology news :

1. Breakthrough developments in rheumatoid arthritis reported
2. Breakthrough for treatment of fatal heart condition
3. Breakthrough vaccine to treat chemo-resistant ovarian cancer
4. Breakthrough in understanding type 2 diabetes as key genes identified
5. Breakthrough in nanodevice synthesis revolutionizes biological sensors
6. Breakthrough for future exploration unrecoverable gas reserves
7. Breakthrough by MUHC researcher has major implications
8. Breakthrough offers new tool for studying degenerative disease
9. Breakthrough in brain injury study at University of Leicester
10. Breakthrough for stem cell research
11. Sciences Breakthrough of the Year: Watching evolution in action

Post Your Comments:
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
(Date:5/21/2015)... Prussia, PA (PRWEB) May 21, 2015 ... O’Neill has joined the firm as senior statistician and ... 30 years of experience in the management and analysis ... biologics, pharmaceutical and chemical industries. , “We’re delighted to ... longstanding capabilities in data analytics,” said Dr. Philippe Cini, ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has announced ... Insights" report to their offering. Technical ... the Health and Wellness sector and has identified top ... in the year 2015. The research service provides an ... wellness technologies that are anticipated to have the highest ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research and ... addition of the "Global Cell Therapy Market Outlook ... Utilization of cell therapy in tissue and regenerative medicine ... are no other options which could help in the ... in this segment but they are unable to form ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Top Technologies in the Health and Wellness Industry 2015 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: